Table 2.
Discovery cohort | RA (n = 96) | HC (n = 90) | |
---|---|---|---|
Age, (mean ± SD) | 51 ± 15 | 39 ± 11 | |
Sex, Female (%) | 82 (85.4) | 76 (84.4) | |
Disease duration years, (mean ± SD) | 10.0 ± 8.7 | ||
SJC, (mean (range)) | 4 (0-28) | ||
TJC, (mean (range)) | 6 (0-28) | ||
ESR, (mm/hour, (mean ± SD)) | 35.6 ± 27.2 | ||
CRP, (mg/L, (mean ± SD)) | 21.2 ± 31.9 | ||
RF positive (%) | 47 (49.0) | ||
CCP positive (%) | 48 (50.0) | ||
DAS28 score, (mean ± SD) | 4.2 ± 1.6 | ||
ANA positive (%) | 15 (15.6) | ||
Low C3 (%) | 3 (3.1) | ||
Low C4 (%) | 7 (7.3) | ||
IGA, (g/L, (mean ± SD)) | 2.8 ± 1.2 | ||
IGG, (g/L, (mean ± SD)) | 14.7 ± 5.1 | ||
IGM, (g/L, (mean ± SD)) | 1.2 ± 0.6 | ||
Current drug use | |||
Oral glucocorticoid treatment (%) | 32 (33.3) | ||
DMARD (%) | 45 (46.9) | ||
Oral anticoagulant (%) | 2 (2.1) | ||
Aspirin (%) | 3 (3.1) | ||
Biologics (%) | 6 (6.3) | ||
Tripterygium glycosides (%) | 15 (15.6) |
SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity score (28-joint count); ANA, anti-nuclear antibody; C3, complement 3; C4, complement 4; IGA, immunoglobulin A; IGG, immunoglobulin G; IGM, immunoglobulin M; DMARD, disease modifying antirheumatic drug.